Life Science Nation Newsletter  | January 26,  2017  |  Issue 198

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Jan. 19  - Jan. 25)
Invests in Clinical-Stage Life Science Opportunities Across North America
Looks For Medtech Opportunities, Including Delivery Devices, Biosensors and Healthcare IT
Invests in Therapeutic Opportunities at Any Stage
Invests Early In Diabetes, Cardiovascular, Infectious Disease and Oncology
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

LSN Book

LSN Videos
By Cole Bunn, Senior Research Analyst, LSN

As we look forward to 2017, there is certainly a lot of speculation regarding how the biotech sector will fare in the wake of a lackluster 2016 for public market performance, M&A transactions and venture funding for life science/healthcare companies, not to mention the intense pricing pressure drug makers are now facing. All things considered, most biotech folk are optimistic on what the new year will hold for the life science startups and the healthcare sector as a whole...

By Lucy Parkinson, Director of Research, LSN

2016 has been a mixed year for pharma, with new drug approvals well down from the 2015 highs, but major pharma firms continue to search outbound for the drugs of the future. The LSN Licensing Deals Platform provides detailed information on announced pharma deals, and this data allows us to take a look at the overall dealmaking landscape in 2016.

The LSN Licensing Deals platform doesn't include M&A, and only covers deal announcements in which some financial information was stated, such as upfront and milestone payment amounts and/or a royalty percentage...

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

During JPM this year, close to 1,000 investment professionals from China gathered in San Francisco, according to unofficial statistics. What hot sectors are they looking for? How can you initiate and maintain a relationship with them? At RESI San Francisco, entrepreneurs and investors filled up the Asia Pacific Investors panel room to learn about the nuts and bolts of cross-border investment.

Moderated by Jimmy Lu, Managing Director, WI Harper Group, the panelists include:
  • Judith Li, Partner, Lilly Asia Ventures
  • Lu Zhang, Managing Partner, NewGen Capital
  • Vincent Xiang, Partner, Frontline BioVentures
  • Yao Li Ho, Business Development Director, LYFE Capital